N.myc oncogene amplification in neuroblastoma has been found to be significantly associated with advanced stage disease and tumor progression. However, there is a lack of data on tumors, regarding the relationship between N-myc gene amplification and proliferation activity. Proliferating cell nuclear antigen (PCNA) is a proliferation-induced 36 kD nuclear protein that is the auxiliary component of DNA polymerase b. PCNA levels in tissues have been found to correlate with proliferative activity. We have examined PCNA levels in neuroblastomas in relation to N-myc gene amplification and tumor stage. Statistically, significantly higher levels of PCNA were observed in tumors with an amplified N-myc gene relative to tumors with a single gene copy. The highest levels of PCNA were observed in advanced stage tumors with an amplified N-myc gene.
Introduction
A large number of molecular events and factors responsible for progression of cells during the cell cycle have been defined [1] . PCNA was originally described as a nuclear antigen to which some patients with systemic lupus erythematosis develop autoantibodies [2] [3] [4] . In contrast to resting cells IITo whom correspondence should be addressed.
synthesize PCNA constitutively and in amounts proportional to the degree of transformation [5] [6] [7] . A polypeptide designated cyclin was independently found to be preferentially synthesized during the S phase and has been found to be identical to PCNA [5, 6, 8, 9] . In normal cells that have been induced to proliferate, for example following mitogen stimulation of resting peripheral blood lymphocytes, PCNA expression increases from the late G1 phase through the S phase of the cycle [5, 9] .
Exposure of exponentially growing cells to antisense oligodeoxynucleotides to PCNA resulted in complete suppression of DNA synthesis and mitosis, indicating an important role for PCNA in cell proliferation [10] . Expression of PCNA is elevated in a wide range of abnormally proliferating cells, including carcinomas of the breast, colon, lung, kidney, stomach, skin, ovaries and testes [11] . PCNA positivity has been found to correlate with mitotic activity and tumor grade [11] . In chronic myeloid leukemia, PCNA expression is elevated during blast crisis [12] . We have previously studied PCNA expression in childhood acute leukemia and have observed differences in PCNA levels between lineage-related subtypes that have a different prognosis [13] .
Neuroblastoma is a solid tumor of childhood which has a variable outcome related to stage and amplification of the N-myc oncogene [14] [15] [16] [17] [18] [19] [20] [21] [22] . To date, few data are available regarding the relationship between N-myc gene amplification and in vivo proliferative activity of tumors. In this study, we have examined the variability of PCNA expression in neuroblastoma in relation to tumor stage and N-myc gene copy number. Our findings indicate that higher PCNA levels occur in tumors with an amplified N-myc gene relative to tumors with a single N-myc gene, and in metastatic relative to non-metastatic tumors.
Materials and methods

Tumors and cell lines
Tumors were obtained from 40 newly diagnosed pediatric patients at the time of surgery, prior to chemotherapy, and represented all clinical stages of the disease, from localized (stage I) to metastatic disease (stage IV). Informed consent was obtained in all cases. These tumors were analysed previously for the expression of two other proliferation-related proteins, namely Op18 and p19/nm23 [23, 24] . Of the 40 tumors studied for their content of PCNA, four belonged to the special group of infants with metastatic disease (stage IV-S), associated with a very good outcome, all of whom had a normal N-myc gene copy number. N-myc gene copy number was determined as described previously [14] . Fifteen neuroblastoma cell lines were also analysed for their PCNA content by two-dimensional (2-D) PAGE. Five cell lines had a non-amplified and 10 had an amplified N-myc gene (25-150 copies). All cell lines were derived from advanced stage tumors.
The cell line KCNRP-9 was treated with retinoic acid as described previously [24] [25] [26] .
2-D PAGE
Samples of approximately 200/zg of tumor tissue were cut from larger size pieces and solubilized by addition of (per liter) 8 M urea, 20 ml of Nonidet P-40 surfactant, 20 ml of ampholytes (pH 3.5-10), 20 ml of 2-mercaptoethanol, and 0.2 mM of phenylmethylsulfonyl fluoride in distilled deionized water. For neuroblastoma cell lines, 2 x 106 cells were similarly solubilized. Two-dimensional PAGE was performed as described previously [27] . In most cases 20-30 ~1 aliquots containing approximately 70/.tg of protein were applied immediately onto isofocusing gels. First dimension gels contained 50 ml of ampholytes per liter (pH 3.5-9.0). Isofocusing was performed at 1200 V for 16 h and 1500V for the last 2h. Twenty gels were run simultaneously. For the second dimension separation, an acrylamide gradient of 11.4-14.0 g/dl was used. Protein spots in gels were visualized using the silver-staining technique [28] .
Quannfication of PCNA Spot detection and quantitation were performed as described previously [29] . Each gel was scanned in a 1024 x 1024 pixel format, giving 160/zm as the pixel width. The digitized images were assigned coded numbers and were analysed for the presence and quantity of PCNA, without knowledge of the sample to which a gel image correspond. PCNA was identified, based on its characteristic migration and position in relation to neighboring landmark spots that were present in all gels included in this study and that were recognizable to the analyst. The PCNA spot, as well as 20 other reference spots, were quantified by placing a cursor on each spot, on the graphics monitor, and typing in the name for the spot. The reference spots correspond to cellular proteins, most of which were identified recently by our group on the basis of sequencing information (manuscript in preparation). The integrated intensity of each spot was measured in units of optical density x mm 2. Data on these spots were analysed using the Michigan Interactive Data Analysis System, a statistical software package. The 20 reference spots were used to adjust the PCNA spot-integrated intensity as described previously [29] , to compensate for any variability in protein loading or staining between gels. For comparison of spot intensities between groups, ANOVAs, t-tests and calculation of correlation coefficients were used where appropriate.
Results
We previously identified PCNA in 2-D gels on the basis of its molecular weight, pI, and its characteristic location relative to other landmark proteins ( Figure 1 ). The polypeptide spot that was presumed to be PCNA increased substantially following phytohemagglutinin stimulation of peripheral blood lymphocytes. Its identity was further confirmed by N-terminal sequencing which yielded the sequence K,F,E,A,R,L,V,Q,G,S,I,L,K that uniquely corresponded to PCNA [13] . In this study, the identity of PCNA in neuroblastoma-derived 2-D PAGE patterns was confirmed by Western blotting [30] . An antibody preparation to PCNA (19F4) reacted strongly and exclusively in 2-D gels of neuroblastoma tumors with the polypeptide presumed to be PCNA. 
Differential expression of PCNA in relation to tumor stage and N-myc gene copy number
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PCNA levels in neuroblastoma cell lines
Fifteen neuroblastoma cell lines were analysed for their PCNA content. All neuroblastoma cell lines exhibited high levels of PCNA (Table 2) Neuroblastoma cell lines can be induced to differentiate with retinoic acid (RA) [24] [25] [26] . The steady-state level of N-myc protein has been shown to decrease following RA treatment of cell lines in which the N-myc gene is amplified [25] .
An increase in the number of receptors for the nerve growth factor (NGF) was reported to be associated with neuroblastoma differentiation following RA treatment [31] . We therefore examined the effect of RA treatment on PCNA expression using the neuroblastoma cell line KCNRP-9 which contains 75 copies of the N-myc
gene. There was a slight drop in PCNA mean integrated intensity by day 2 relative to control cells treated with ethanol alone (mean intensity 1.74 vs 2.28, P = 0.10). By day 10 the difference between retinoic-treated and control cells (Figure 3 ) was significant (0.86 and 2.29, P < 0.001).
Discussion
Neuroblastoma is a common childhood tumor which originates in neural crest derived cells. Children with the tumor present with local, regional or metastatic disease. In studies of neuroblastoma tumors, amplification of the N-myc oncogene has been found to be significantly associated with advanced stage disease and rapid tumor progression [14] [15] [16] [17] [18] 22] . In this study, we have examined the expression of PCNA in untreated level observed in T-ALL, a subtype usually associated with high proliferative activity and a high tumor load. While direct comparisons between PCNA levels in lymphoid cells and in neuroblastoma are of limited use, the wide range of PCNA expression in neuroblastoma, approximating the range observed between resting lymphocytes and T-ALL, suggests a wide range of proliferative activity in different tumors.
To date, there have been limited studies of proliferation kinetics in neuroblastoma [32, 33] . Mean generation times for undifferentiated tumors range from less than 13 h to 260 h, with potential tumor doubling time ranging from 20 to 415 h.
[3H]Thymidine labeling indexes have been reported to vary between 3 and 28%, and growth fractions between 0.48 and 0.58. In neuroblastoma, the duration of the cell cycle has been found to vary by a factor of up to 20, from 0.5 to 11 days. The duration of DNA synthesis, the G2 phase and mitosis were rather constant in a particular case, whereas the G1 phase is a variable parameter [32, 34] . In these studies the relationship between proliferation kinetics and N-rnyc gene copy number was not determined. In another study, tumors with an amplified N-myc gene were found to have a higher percentage of cells in S phase, though the relationship was not statistically significant and no definitive conclusions could be made (P = 0.14) [35] . The PCNA data we have obtained, with statistically highly significant differences between tumors with a single N-rnyc gene copy and tumors with an amplified N-myc oncogene, suggest differences in proliferative activity in neuroblastoma related to the status of the N-myc gene.
Cell cycle differences between neuroblastoma tumors could be related to differences in rate limiting factors that control progression of tumor cells through the cell cycle. Such differences have been implicated for certain tumors [34] . Control of the rate of proliferation of tumors may occur at the GI/S interface, a phase during which PCNA synthesis peaks. Therefore, among neuroblastoma tumors, those exhibiting relatively high PCNA level may contain a greater number of cells that can progress through the cell cycle. It is possible that increased N-myc protein level resulting from N-myc gene amplification or from prolonged Nmyc mRNA or protein half-life [35, 36] It is of interest that among tumors with a single N-myc gene copy, tumors that belong to stage IV and IV-S display equivalent PCNA levels. While these tumors have a markedly different outcome, they share a high tumor load. It is likely therefore that PCNA levels directly reflect tumor proliferative activity which in certain cases as in IV-S tumors may not be related to prognosis. We have previously reported that two other cellular polypeptides, Op18 and p19/nm23, that are induced in proliferating cells, displayed differences in their levels between advanced stages III and IV and stages with a good prognosis including stage IV-S [23, 24] . Several other polypeptides observed in 2-D gels which have yet to be identified have exhibited variable expression in neuroblastoma. Sequencing studies of these polypeptides are currently being undertaken. Detailed analysis of the extent of differential expression between neuroblastoma tumors of polypeptides that play a role in cell proliferation is likely to improve our understanding of the molecular basis of tumor heterogeneity that may be responsible for a varied outcome in neuroblastoma.
